Hofouf, Saudi Arabia

Melendran Pillay


Average Co-Inventor Count = 9.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Hofouf, SA (2022)
  • Durban, SA (2024)

Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Melendran Pillay: Innovator in Antitubercular Compounds

Introduction

Melendran Pillay is a notable inventor based in Hofouf, Saudi Arabia. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antitubercular agents. With a total of 2 patents, his work focuses on innovative compounds that aim to combat tuberculosis.

Latest Patents

Pillay's latest patents include the development of 1-substituted benzoyl-4-bromopyrrolo[1,2-a]quinoline-3-carboxylate derivatives as antitubercular agents. These compounds are designed specifically for treating tuberculosis and represent a promising avenue for future therapies. Additionally, he has worked on antitubercular compounds that include trisubstituted indolizines, which have various structural modifications to enhance their efficacy.

Career Highlights

Melendran Pillay is affiliated with King Fahd University of Petroleum and Minerals, where he contributes to research and development in the field of pharmaceuticals. His academic and professional background has equipped him with the skills necessary to innovate in the area of drug development.

Collaborations

Pillay has collaborated with esteemed colleagues such as Katharigatta N Venugopala and Mahesh Attimarad. These partnerships have fostered a collaborative environment that enhances the research output and innovation in their projects.

Conclusion

Melendran Pillay's work in developing antitubercular compounds showcases his commitment to addressing significant health challenges. His innovative approach and collaboration with fellow researchers position him as a key figure in the fight against tuberculosis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…